Drawing on broad industry expertise, our Board of Directors provides strategic oversight and guidance to support our long-term growth and mission
Jeremie joined Ardena as Chief Executive Officer in 2024.
He brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience building and growing businesses globally, expending into new markets, and leading large-scale transformations in both publicly traded and privately held companies.
Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO, and during his tenure there, led the successful acquisition and integration of multiple companies.
Alan has over 30 years private equity experience, witrh a strong track record of dedicated healthcare investing.
Alan is currently a member of the board at Ardena, Sterling, Alcami, RoslinCT, and X-Chem and previously Quotient Sciences until its successful exit.
Previously, Alan was a board member at 3i plc, led the build-out of the 3i Europe office network, and founded 3i’s healthcare sector team as Global Head of Healthcare. Subsequently, Alan was founder, CEO and Chairman of the Investment Committee at Hermes GPE, an active co-investor in private equity-backed healthcare.
Alan has over 30 years private equity investment experience, with a strong track record of dedicated healthcare investing.
He is currently a member of the board at Ardena, Alcami, RoslinCT, X-Chem, and Sterling and previously Quotient Sciences until its successful exit.
Previously, Alan was a board member at 3i plc, led the build-out of the 3i Europe office network, and founded 3i’s healthcare sector team as Global Head of Healthcare. Subsequently, Alan was founder, CEO and Chairman of the Investment Committee at Hermes GPE, an active co-investor in private equity-backed healthcare.
Alan holds a Bachelor’s degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He was Chair of the BVCA and for a number of years chaired the BVCA Responsible Investment Advisory Board, and is currently Chairman of the European Healthcare Investors Association (EHIA).
Sabina is an investment professional with a background in both accounting and corporate finance.
Having joined GHO in 2015, Sabina currently works closely with Ardena and DDC, as well as previously with Caprion Biosciences prior to GHO Capital’s successful exit.
Prior to GHO, Sabina was with 123Venture in Paris where she was responsible for evaluating and executing mezzanine financing opportunities across Europe.
Ariette brings over 30 years of experience in clinical research and global healthcare logistics to Ardena’s Board of Directors. She currently serves as President of UPS Healthcare Precision Logistics, where she leads a global team of 4,000 employees across 220+ countries and territories.
Throughout her career, Ariette has held senior executive roles spanning global marketing and business development, pricing, project management, and operations.
Get in touch to see how we can craft your path to the clinic with dedicated capabilities.